{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:48Z","timestamp":1746417768857,"version":"3.40.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Hypercalcemia is a common finding in patients with advanced-stage cancers. Paraneoplastic hypercalcemia is commonly associated with dismal prognoses, with survival rates of about 3 months. In this paper, we report on a patient with advanced chronic lymphocytic leukemia and non-small cell lung carcinoma who developed severe hypercalcemia and discuss the diagnosis and treatment of this metabolic complication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 56-year old male with a 2-year history of Rai stage IV chronic lymphocytic leukemia presented with life-threatening hypercalcemia. Positron emission tomography\/computed tomography revealed a suspicious lung lesion. A transbronchial biopsy was performed from the upper left lobe. Due to the small size of the specimen, immunohistochemical markers were performed and revealed positive staining for cytokeratin 7 and negative for TTF-1, napsin A and p 40, which were consistent with non-small cell lung carcinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Humoral hypercalcemia of malignancy was diagnosed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>The patient was treated with saline infusion, calcitonin, intravenous pamidronate, followed with denosumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The hypercalcemia was successfully treated and the patient's calcium levels returned to normal. Further evaluation revealed a non-small cell lung carcinoma as a second primary malignancy. The patient was treated with venetoclax for his refractory CLL and received chemotherapy and immunotherapy for lung adenocarcinoma. Several days after starting venetoclax, he developed Legionella pneumonia and short time after the second course of chemotherapy, a severe sepsis occurred and he passed away.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Coexistence of 2 unrelated malignancies, whichever could be a reason for hypercalcemia of malignancy is a rare event. Severe hypercalcemia, which is possible but rare feature of CLL should be a reason for further prompt evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024982","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T04:52:46Z","timestamp":1617857566000},"page":"e24982","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Severe hypercalcemia in a patient with chronic lymphocytic leukemia and non-small cell lung carcinoma"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-1271","authenticated-orcid":false,"given":"Elena Chertok","family":"Shacham","sequence":"first","affiliation":[{"name":"Department of Internal Medicine E, HaEmek Medical Center"},{"name":"Endocrinology Unit, HaEmek Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna Chap","family":"Marshak","sequence":"additional","affiliation":[{"name":"Hematology Unit, HaEmek Medical Center, Afula"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"Brikman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine E, HaEmek Medical Center"},{"name":"Faculty of medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Dori","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine E, HaEmek Medical Center"},{"name":"Faculty of medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avraham","family":"Ishay","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, HaEmek Medical Center"},{"name":"Faculty of medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.canep.2015.10.012","article-title":"Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the clinical practice research datalink database","volume":"39","author":"Jick","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Medicine"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","author":"Hu","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukaemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2019.07.057","article-title":"Real-life insight in to ibrutinib CV adverse events","volume":"74","author":"Bergler-Klein","year":"2019","journal-title":"JACC"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hon.2502","article-title":"Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia","volume":"36","author":"Innocenti","year":"2018","journal-title":"Hemat Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1136\/bmj.h2723","article-title":"The diagnosis and management of hypercalcaemia","volume":"350","author":"Minisola","year":"2015","journal-title":"BMJ"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1210\/jc.2014-4250","article-title":"PTHrP-mediated hypercalcemia: causes and survival in 138 patients","volume":"100","author":"Donovan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"North Am J Med Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","journal-title":"Cancer Invest"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"key":"R16-20250504","first-page":"691","article-title":"Symptomatic hypercalcemia in a patient with B-cell chronic lymphocytic leukemia - a case report and review of the literature","volume":"30","author":"Koutroumpakis","year":"2016","journal-title":"In Vivo"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.clml.2015.06.007","article-title":"PTHrP-induced refractory malignant hypercalcemia in a patient with chronic lymphocytic leukemia responding to denosumab","volume":"15","author":"Salahudeen","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R18-20250504","first-page":"119","article-title":"Parathyroid-hormone-related-protein associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphoma","volume":"91","author":"Sch\u00f6ttker","year":"2006","journal-title":"Haematologica"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0300-2977(98)00099-0","article-title":"Parathyroid hormone related protein(PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia","volume":"54","author":"Vlasveld","year":"1999","journal-title":"Neth J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2141.1994.tb06752.x","article-title":"Hypercalcaemia in B cell chronic lymphocytic leukaemia","volume":"87","author":"Fain","year":"1994","journal-title":"Br J Haematol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000314646","article-title":"A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone related peptides","volume":"124","author":"Kampfenkel","year":"2010","journal-title":"Acta Haematol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1211::AID-CNCR21>3.0.CO;2-1","article-title":"Hypercalcemia may indicate Richter's syndrome: report of four cases and review","volume":"79","author":"Beaudreuil","year":"1997","journal-title":"Cancer"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000455913","article-title":"Richter's syndrome with hypercalcemia induced by tumor-associated production of parathyroid hormone-related peptide","volume":"10","author":"Watanabe","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4149\/endo_2014_03_113","article-title":"The coexistence of renal cell carcinoma and diffuse large B-cell lymphoma with hypercalcemic crisis as the initial presentation","volume":"48","author":"Yilmaz","year":"2014","journal-title":"Endocr Regul"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:20:38Z","timestamp":1746339638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024982"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":24,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024982","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"2020-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}